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Introduction
The trypanosomatidae family comprises several genera, some of which undergo cyclical development in both vertebrate and invertebrate hosts. These include the mammalian infective Trypanosoma and Leishmania species, responsible for potentially fatal diseases in both humans and animals. About half a billion people dwelling in tropical and sub-tropical areas of the World are at risk of contracting these diseases, with more than 20 million people infected with the pathogens that cause them, resulting in extensive suffering and more than 100,000 deaths per year [1] .
The treatment options for the neglected tropical diseases caused by these pathogens have always been limited to a few relatively ineffective drugs, most of which were discovered over 50 years ago. These drugs have been reported to possess several drawbacks and limitations in their efficacy. For example, the conventional drugs for treating Human African Trypanosomiasis (HAT) such as Suramin, Pentamidine, Melarsoprol and Eflornithine vary in effectiveness depending on the stage of the disease and the trypanosome species involved, require long periods of administration and are associated with toxicities and drug resistance [2] .
Chagas disease front-line drugs Nifurtimox and Benznidazole are associated with severe side effects, long treatment periods (>60 days) and variations in sensitivity of the parasites [3] [4] .
Miltefosine is currently the only oral treatment for visceral leishmaniasis (VL), but its clinical use has been limited due to its teratogenic effects and increasing reports of treatment failures [5] . AmBisome, previously considered effective against VL, requires intravenous administration, is very expensive and is associated with side effects. The lack of formulations for paediatric patients and pregnant women and the unavailability of these trypanosomatid drugs due to low production [6] are clear obstacles in terms of drug accessibility to the people who really need them. There is, therefore, an urgent demand to identify novel drug targets and develop new therapies for these neglected diseases.
A C C E P T E D M
A N U S C R I P T One approach to drug discovery is through high throughput screening (HTS) of diverse compound collections for identification of active hits by whole cell screening. Although several efforts have been made, drug discovery through HTS for these trypanosomatid diseases has been a slow process. This has been due, among other reasons, to a requirement for expensive containment facilities and costly serum-containing media, essential for propagation of these parasites. These and other factors renders drug discovery through HTS for these parasites impractical in resource-limited countries where the burden of the disease is highest.
Crithidia fasciculata is a non-mammalian infective lower trypanosomatid, which can be handled in a standard laboratory without specific biosafety issues. C. fasciculata has relatively fast growth kinetics and can be easily and inexpensively grown to high cell densities in liquid media, which can be fully defined and serum-free. C. fasciculata represents a very interesting model to study biological cellular and genetic processes unique to members of the family Trypanosomatidae. This kinetoplastid has a very similar cellular machinery and is phylogenetically related to the human pathogenic trypanosomatids (T. brucei, T. cruzi and especially Leishmania spp. with whom it is more closely related) and is easily amenable to molecular, genetic and biochemical analyses.
Over the past few decades C. fasciculata has been utilised as a model system to study the biochemical, cellular, and genetic processes unique to members of the family Trypanosomatidae. This has allowed researchers to uncover cellular and/or biochemical processes that ultimately could be exploited for the development of novel therapies for the related pathogenic trypanosomatids [7] [8] [9] [10] [11] [12] .
Although it should be noted that C. fasciculate are unable to invade / and are non-pathogenic to mammalian cells, and certain aspects of their proteome and mitochondria are different compared to Leishmania, probably reflecting differences in their carbon-source usage [13] .
Here we explore the use of C. fasciculata as a low-cost model organism in determining the anti-crithidial activities of compounds from collections known to have anti-parasitic activity.
We repurposed the current Medicines for Malaria venture (MMV) Pathogen box (http://www.mmv.org/) and the GlaxoSmithKline (GSK) Tres Cantos anti-kinetoplastid chemical boxes to screen for compounds active against C. fasciculata. The MMV chemical box contains 402 diverse drug-like compounds selected with activity against diseases such as Chagas disease, malaria, HAT, tuberculosis and schistosomiasis [14] . The GSK antikinetoplastid compounds are assembled into three boxes according to the organism they are
T. cruzi (Chagas-Box) and T. brucei (HATBox), with each box containing ~200 compounds [15] . These chemical boxes have been assembled and all data made publically available (https://www.ebi.ac.uk/chemblntd) with the aim of facilitating and stimulating the drug discovery for these neglected diseases.
Materials and methods

Reagents
All chemicals and reagents used in the experiments were purchased from Sigma-Aldrich.
Parasites and cell culture
The C. fasciculata promastigotes clone HS6 were grown at 27°C with gentle agitation in axenic serum-free defined media containing yeast extract (5 mg/mL), tryptone (4 mg/mL), sucrose (15 mg/mL), triethanolamine (4.4 mg/mL) and Tween 80 (0.5%) and supplemented with 10 µg/mL of haemin. The parasites were sub-cultured every 2-3 days to ensure log growth phase for subsequent experiments.
Compound libraries
Chemical boxes were kindly provided by MMV and GSK Tres Cantos. The MMV pathogen box contained 402 chemicals representing compounds that were active against one or more of 12 distinct pathogens (see https://www.pathogenbox.org/about-pathogen-box/supportinginformation). Individual compounds had only been tested to confirm activity against the pathogen for which the compounds were first reported to be active, and have not been tested against the other pathogens represented in the pathogen box. All compounds have been tested for cytotoxicity: typically, they were five-fold less potent against a human fibroblast cell line (MRC-5) than the pathogen (https://www.pathogenbox.org/about-pathogen-box/supportinginformation).
The three GSK kineto boxes (Leish-Box, Chagas-Box and HAT-Box), with each box containing ~200 compounds assembled by Pena and his colleagues [15] as previously discussed, were donated by GSK Tres Cantos. The supplied information included details on the pathogen against which the compound had shown activity, compound cytotoxicity, as well as other useful data such compound ID, batch ID, trivial name, molecular weight, salt, and cLogP. More information about these compounds can be accessed online via ChEMBL-NTD (https://www.ebi.ac.uk/chemblntd).
Both the MMV and the GSK compounds were supplied in 96-well plates, containing 10 μL of 10 mM dimethyl sulfoxide (DMSO) solution of each compound. Each compound was then diluted with phosphate buffer saline (PBS) to a working concentration of 2.5 mM (DMSO,
) and aliquoted into multiple plates. The compounds were stored at -80°C and thawed at room temperature prior to use. Each of the 400 compounds was screened in quadruplicate at a concentration of 100 µM (DMSO, 0.5% final concentration) in 96-well plates.
C. fasciculata viability assay optimization
Although resazurin-reduction assay has been extensively used for screening drug susceptibility of various cell types, it has not yet been applied to Crithidia. Therefore, a number of conditions such as the growth kinetics of cells, maximum cell densities, the incubation period, the resazurin concentration and the DMSO concentrations had to be considered and optimised for the resazurin-reduction assay to work as a screening tool in this system. A stock solution of 12.5 mg/mL resazurin in PBS was used in all assays. All fluorescence measurements in this study were performed with the Spectra Max Gemini XPS Microplate reader (Molecular Devices) with excitation and emission wavelengths of 560 nm and 590 nm. were performed twice and the results were averaged over eight replicate wells.
Determining the relationship between cell density and the resazurin fluorescence
To determine the relationship between cell density and the fluorescence signal, the parasites in the logarithmic phase of a stock suspension of 1 x10 6 cells/ml were serially diluted (100 µL)
into 96-well plates followed by addition of 10 µL of resazurin. Plates were incubated at 27°C
and fluorescence measured after every 1 hour for a period of 4 hours. The experiments were performed twice and the results were averaged over eight replicate wells.
Determining the effect of DMSO concentrations on the assay signal
90 µl of medium containing C. fasciculata choanomastigotes (5,000 cells/mL) was inoculated into a 96-well plate and incubated for 24 hours. 10 µL of various (0.5 -9.0 % final)
concentrations of DMSO diluted in the medium were then added to the plates and further incubated for 24 hours. The experiments were performed twice and the results were averaged over eight replicate wells.
Primary screening assays
C. fasciculata choanomastigotes in the log phase of growth were diluted 1:20 in the axenic growth media, and 20 µL was counted using a hemocytometer. For anti-crithidial activity, compounds were added to the test plates with medium containing the parasites (density ~5 x 10 4 cells/ml) to achieve a final compound and DMSO concentration of 100 µM and 0.5%, confirmation rate, compounds were considered confirmed when the normalized anti-parasitic activity was equal to or greater than 80% (≥80%) at 100 µM concentration.
Dose-response assessments of active compounds
The compounds which showed ≥80% inhibition when tested at 100 µM concentration in at least one biological replicate were retested in 10-point dose response, two-fold serial dilution experiments starting at various compound concentrations with the parasites seeding density of ~5 x 10 4 cells/mL. Wells containing the 0.5% DMSO growth media with no cells and 0.5% DMSO growth media with cells but no drug, served as 100% inhibition and 100% growth controls, respectively. 10 µL of the resazurin solution was added after 44 hours incubation and fluorescence development was determined after a total drug exposure time of 48 hours. The obtained fluorescence data was analysed with the graphic data analysis software GraFit (Erithacus Sofware) which calculated EC50 values by linear regression from the sigmoidal dose inhibition curves. Compounds which did and did not yield an EC50 value within the confines of the analysis parameters were simply expressed as the true active and false active compounds, respectively. A few compounds of interest, which had comparably low EC50 values were selected from the top ten lists, purchased from commercial sources (Sigma-Aldrich) and screened to finally confirm their activities. EC50 was defined as the concentration of a compound required to decrease the C. fasciculata viability by 50% compared to those grown
in the absence of the test compound. All experiments were performed twice, with each drug concentration in quadruplicate. For standardisation, EC50 values were converted to pIC50.
Results and discussion
Resazurin-reduction C. fasciculata cell-based assay optimization
In order to determine the maximum cell numbers that could be used for developing the screening assay, the growth kinetics of C. fasciculata parasites growing in our formulated serum-free medium was analysed using the growth curve shown in Supplementary Figure 1 .
The parasites grew quite robustly under axenic conditions in vitro and reached the stationary phase after 3 days. Similar C. fasciculata growth kinetics for in vitro culture systems have been reported elsewhere [16] [17] . The average generation time was determined according to the Popp and Lattorff [18] equation and gave an estimation of approximately 4.5 hours. The doubling time observed is shorter than the doubling time (6.8 hours) reported for T. brucei brucei bloodstream forms when grown in HMI-9 supplemented with 10% foetal calf serum [18] and 7 hours for some Leishmania species (S. Menzies, personal communication).
A linear relationship was observed between the incubation time and the fluorescent development of resazurin reduction (Supplementary Figure 2) . However, low dye concentrations gave relatively higher fluorescent signal as compared to higher concentrations.
A similar independent relationship between resazurin concentration and the fluorescent signal have been previously reported in alternative assays [19] [20] . This is due to quick reduction of small volumes of the dye by the cells or perhaps high concentrations of resazurin salts having an inhibitory effect on cell growth and metabolism. For higher cell inoculums, the fluorescent signal easily reached saturation within a few minutes when a 5% (w/v) (5 µL) dye concentration was used but a strong fluorescent signal after 4 hours incubation was obtained with 10% (10 µL) resazurin. Therefore 10% resazurin was selected as an ideal dye concentration for all of the assays.
Nevertheless, the dye was linearly reduced proportionally to the incubation period (Supplementary Figure 3) . However, for high cell densities such as 8 x 10 7 /mL and 4 x 10 7 /mL, the fluorescence signal reached saturation after 1 hour and 2 hrs incubation, respectively. However, after 4 hrs incubation, a very strong signal from 2 x 10 7 cells/mL gave the best maximum fluorescence to background signal ratio of 9:1. The reported signal to background ratio (S/B) is higher than the 3:1 obtained from T. b. gambiense but lower than that from T. b. rhodesience (15:1) in similar assays [20] . These differences could be attributed to variations in dehydrogenase activity responsible for metabolizing resazurin or reduced uptake
of the dye substrate among the parasites. Differences in the fluorescence analysers, concentrations of the dye used, as well as the composition of media used to culture these parasites could potentially also account for some of the variations observed.
Since compounds library collections were diluted in DMSO, which is known to be toxic to cells at various concentrations, it was necessary to determine its effects on the viability of the C. fasciculata by exposing the parasites to various DMSO concentrations (Supplementary   Figure 4) . The C. fasciculata parasites were able to tolerate maximum DMSO concentrations of up to 0.5% with no significant decrease in fluorescent signal. This DMSO sensitivity is slightly higher than the 0.42% reported for bloodstream form T. b. brucei strain 427 by Sykes and Avery [18] , but lower than the 1% reported for bloodstream forms of T. brucei strain 427
and T. congolense STIB910 [21] . After optimizations, the assay performance and its capabilities to discriminate the activities of different compounds was evaluated by calculating the Z' factor [22] . Statistically, the assay performed well with an average Z' factor of 0.7 (a maximum plating cell density of 5 x 10 4 cells/mL, 48 hrs incubation, 10% v/v resazurin and maximum of 0.5% DMSO). The distribution of Z' factor (a Z' factor between 1-0.5 is an acceptable for a robust assay) in a total of 100 randomly selected plates is shown (Figure 1 ). This showed that the assay was able to discriminate compounds with different levels of inhibition during the screening process.
Screening the chemical boxes for anti-crithidial compounds
Utilizing conditions established during optimization, the resazurin-based C. fasciculata assay was used to screen for anti-crithidial compounds from the open access MMV pathogen box and GSK Tres Cantos chemical boxes.
Using an inhibition cut-off of ≥80%, the primary screening of the MMV pathogen box led to the identification of 91 (23%) compounds with inhibitory activities at 100 µM against C.
fasciculata. The dose-response experiments of the 91 compounds revealed 72 (79%) were true active compounds, representing an overall hit rate of 18% (Figure 2) . The profiles and in vitro anti-crithidial activities of all compounds in the MMV pathogen box are shown (Supplementary Table 1 ). Ten compounds were picked based upon their potency and
selectivity from these confirmed true active compounds ( Table 1) . The screening revealed compounds (1 and 6) with a common 2-(pyridin-2-yl) pyrimidin-4-amine chemical scaffold and also compound 9 containing a pyrazol (3, 4) pyrimidin-4-amine. Derivatives of the pyrimidin-4-amine scaffold have been previously studied for their inhibitory activities against various protein kinase and cytochrome 51(CYP51) enzymes [15, 23] . The potency of compound 1, a 2-pyridyl-4-aminopyrimidine derivative, is proposed to be due to it targeting methionine aminopeptidases in Plasmodium, and activity against all the three pathogenic kinetoplastids is also reported [14] . Of note, compounds 3, 4 and 5 all have ~10 nM EC50 values against Crithidia. Compound 5 bearing a diaminoquinazoline moiety known to target the dihydrofolate reductases, was also found to possess sub-micromolar inhibitory activity against asexual stage of P. falciparum parasites [14] .
Using our predefined activity criteria (inhibition cut-off of ≥80%), the primary screening of a
T. brucei GSK box identified a total of 66 (35%) compounds with inhibitory activities against
C. fasciculata of which 42 (64%) were confirmed true active after retesting, representing an overall hit rate of 22% (Figure 2) .
The primary screening of T. cruzi and Leishmania boxes revealed 101 (46%) and 122 (67%)
compounds with inhibitory activities against C. fasciculata, of which 68 (67%) and 89 (73%)
were confirmed true active after retesting, representing overall hit rates of 31% and 49%, As there are no mammalian nitroreductase homologues, the 5-nitrofuran-2-yl derivatives are potentially useful in anti-parasitic therapy; however, it is well known that most nitro-aromatics are not well tolerated by the patients that take them and often they do not complete the therapeutic regime [5, 6] .
Querying the T. cruzi box hits ( Table 3) shows two more nitro-heterocyclic analogues (21 and .
Collectively, the data presented here and reported elsewhere in the literature suggests that 2-(pyridin-2-yl) pyrimidin-4-amine (or a structurally similar scaffold) can form the basis of a pan-anti-kinetoplastid compound series targeting the same process in different kinetoplastids.
In conclusion, we have developed a C. fasciculata viability assay that overcomes the limitations of safety and cost issues associated with drug discovery research in pathogenic kinetoplastids.
The commonality of biological and cellular process between C. fasciculata and related pathogenic kinetoplastids shows the usefulness of this study to identify attractive chemical scaffolds within the GSK Tres Cantos and MMV boxes, providing valuable information for future efforts in anti-pathogenic kinetoplastid drug development. Open access chemical boxes A C C E P T E D M A N U S C R I P T Table 1 . Profiles of the top ten hits identified from screening of the MMV pathogen box.
The cytotoxicity data and other relevant information of these compounds are found at (http://www.pathogenbox.org/about-pathogen-box/supportinginformation). pIC50 values are means of two independent assays, which varied < ±50%. Data on cytotoxicity and other information about these compounds is found on (https://www.ebi.ac.uk/chemblntd). pIC50 values are means of two independent assays, which varied < ±50%.
A C C E P T E D M A N U S C R I P T Data on cytotoxicity and other information about these compounds is found on (https://www.ebi.ac.uk/chemblntd). pIC50 values are means of two independent assays, which varied < ±50%.
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